{"brief_title": "Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension", "brief_summary": "The purpose of this study is to evaluate the safety and efficacy of both BETAXON and AZOPT in pediatric patients. Patients will dose with study drug at 8 am and 8 pm daily for twelve weeks. Patients will have vision tested, slit lamp exam, blood pressure and pulse checks at each visit. Patients will have a dilated fundus exam and corneal measurements taken at first and last visit.", "condition": ["Glaucoma", "Ocular Hypertension"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["BETAXON (levobetaxolol HCl)", "AZOPT (brinzolamide)"], "description": ["levobetaxolol suspension, 0.5%", "brinzolamide suspension, 1%"], "arm_group_label": ["Levobetaxolol suspension, 0.5%", "Brinzolamide suspension, 1%"], "criteria": "INCLUSION: - Children 5 years old and younger - require treatment for glaucoma or ocular hypertension - vision is 20/80 or better - cup-to-disc ratio of 0.8 or less EXCLUSION: - do not have abnormal fixation - IOP greater than 36 mm Hg - significant retinal disease - penetrating keratoplasty - severe ocular pathology - optic atrophy - eye surgery in the past 30 days - cardiovascular abnormalities - hypersensitivity to beta blockers, carbonic anhydrase inhibitors or sulfa drugs", "gender": "All", "minimum_age": "N/A", "maximum_age": "5 Years", "healthy_volunteers": "No", "keyword": "Ocular Hypertension", "mesh_term": ["Hypertension", "Glaucoma", "Ocular Hypertension", "Brinzolamide"], "id": "NCT00061516"}